Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,176.75

15.48 (1.33%)

, MYL

Mylan

$36.53

-0.33 (-0.90%)

06:24
12/01/17
12/01
06:24
12/01/17
06:24

Amazon holds preliminary talks with generic drugmakers, CNBC reports

Amazon (AMZN) has held preliminary talks with generic drug companies, including Mylan (MYL) and Novartis' (NVS) Sandoz, regarding the ecommerce giant's possible entry into the pharmacy market, CNBC reports, citing people familiar with the discussions. It is unclear whether Amazon is planning to enter the space as a drug wholesaler or as a retailer but Sandoz said it does not expect the move, which could potentially disrupt the drug distribution industry led by McKesson (MCK), AmerisourceBergen (ABC) and Cardinal Health (CAH), to have a "major impact' on its business. Reference Link

AMZN

Amazon.com

$1,176.75

15.48 (1.33%)

MYL

Mylan

$36.53

-0.33 (-0.90%)

NVS

Novartis

$85.80

0.65 (0.76%)

MCK

McKesson

$147.74

-0.04 (-0.03%)

ABC

AmerisourceBergen

$84.82

0.16 (0.19%)

CAH

Cardinal Health

$59.19

0.08 (0.14%)

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 18

    Jan

  • 18

    Mar

  • 17

    May

AMZN Amazon.com
$1,176.75

15.48 (1.33%)

11/30/17
RBCM
11/30/17
NO CHANGE
RBCM
Amazon.com's AWS offers scale and traction across verticals, says RBC Capital
RBC Capital analyst Mark Mahaney reflects on Amazon.com's AWS event that was much wider attended that in recent years. Mahaney says the company's presentation "highlighted the public cloud's significant appeal in organizations that span nearly every industry vertical". The analyst notes that Amazon's technical prowess make it a clear industry leader as evidenced by AWS expanding its market segment share by 5 points to 44%.
11/30/17
STFL
11/30/17
NO CHANGE
Target $185
STFL
Buy
Costco price target raised to $185 from $179 at Stifel
Stifel analyst Mark Astrachan noted that Costco's (COST) core comp growth for the total company and in the U.S. both came in ahead of consensus expectations. He contends that accelerating comp growth is notable following the recent close of Amazon's (AMZN) deal to buy Whole Foods, as it indicates Costco's value proposition will allow it to coexist with Amazon. The analyst, who projects continued mid-single digit comp growth through at least FY19 at Costco, keeps a Buy rating on the stock and raised his price target to $185.
11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
11/30/17
MKMP
11/30/17
NO CHANGE
Target $1350
MKMP
Buy
Amazon.com price target raised to $1,350 from $1,275 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Amazon to $1,350 and kept his Buy rating, keeping his view of the company as "the best long-term growth story available to large-cap investors today". Sanderson notes that the trend of AWS margin expansion will continue over the coming quarters. The analyst also believes that management can and should continue to reinvest aggressively, adding that "we are still not holding our breath on profits" despite the "richer" business mix.
MYL Mylan
$36.53

-0.33 (-0.90%)

10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
11/07/17
SUSQ
11/07/17
NO CHANGE
Target $47
SUSQ
Positive
Mylan positioned to deliver near-term growth, says Susquehanna
Susquehanna analyst Andrew Finkelstein believes Mylan is favorably positioned relative to peers to deliver near-term growth despite headwinds while advancing a long-term strategy. He said the shares warrant a premium to traditional peers who face tougher growth challenges. Finkelstein reiterated his Positive rating and raised his price target to $47 from $43 on Mylan.
11/07/17
RBCM
11/07/17
NO CHANGE
Target $37
RBCM
Sector Perform
Mylan price target raised to $37 from $32 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Mylan to $37 and kept his Sector Perform rating. The analyst says that in spite of two consecutive challenging quarters that showed the company is not immune to broader sector challenges, Mylan's relative positioning remains favorable to peers, adding that generic Copaxone performance is helpful in the near term.
10/31/17
WELS
10/31/17
NO CHANGE
WELS
Market Perform
Wells sees 'substantial headline risk' for Mylan from probe
Today's expanded collusion probe into generic price fixing will be a "significant overhang" for several generic drug manufacturers, Wells Fargo analyst David Maris tells investors in an intraday research note. For Mylan (MYL), the specific addition of Rajiv Malik, the company's second-highest-ranking executive, creates "substantial headline risk," and may prove to be a distraction to someone many consider one of the key operational managers, Maris adds. He believes the expanding probe will cause many investors to steer clear of an already struggling sector. The analyst has Market Perform ratings on both Mylan and Teva (TEVA). Mylan in midday trading is down 7% to $35.59.
NVS Novartis
$85.80

0.65 (0.76%)

12/01/17
SBSH
12/01/17
DOWNGRADE
Target $380
SBSH
Neutral
Regeneron downgraded to Neutral from Buy at Citi
Citi analyst Robyn Karnauskas downgraded Regeneron Pharmaceuticals (REGN) to Neutral and cut her price target for the shares to $380 from $480. The biotechnology company closed yesterday up 1% to $361.86. The analyst believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. It is hard to believe that RTH258 would not have a price impact, at minimum, on Regeneron's Eylea, Karnauskas tells investors in a research note. The analyst points out that her dermatologist survey came back bullish for Regeneron's Dupixent. While she expects the drug to beat expectations for 2018, the analyst feels this won't be enough to offset the overhang on shares from Eylea competition.
11/20/17
JPMS
11/20/17
DOWNGRADE
Target $82
JPMS
Neutral
Advanced Accelerator downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jessica Fye downgraded Advanced Accelerator Applications (AAAP) to Neutral citing the proposed Novartis (NVS) tender offer. The analyst says the stock is already reflecting a very high likelihood of the deal closing. She raised her price target for the shares to $82 from $53.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/13/17
MSCO
11/13/17
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees limited near-term impact on Regeneron from Novartis data
Morgan Stanley analyst Matthew Harrison noted that Novartis (NVS) presented RTH258 data at the American Academy of Ophthalmology meeting that did show the potential for a commercial "hook," namely an ability to "dry out" hard to treat patients. However, an FDA filing is not expected until the second half of 2018 and key safety details are still needed for a more accurate determination of brolucizumab's possible commercial impact, said Harrison, who sees limited near-term impact on Regeneron (REGN) from the data on the Eylea competitor. He keeps an Equal Weight rating on Regeneron shares.
MCK McKesson
$147.74

-0.04 (-0.03%)

11/09/17
FBCO
11/09/17
NO CHANGE
Target $130
FBCO
Underperform
McKesson price target lowered to $130 from $155 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for McKesson to $130 from $155 on seemingly sustained industry challenges, including lackluster script volume and drug pricing challenges. The analyst reiterates an Underperform rating on the shares.
11/01/17
NEED
11/01/17
NO CHANGE
Target $173
NEED
Buy
McKesson price target lowered to $173 from $178 at Needham
Needham analyst Kevin Caliendo lowered his price target on McKesson (MCK) to $173 despite a solid quarter, saying the positive results were overshadowed by Amazon (AMZN) receiving wholesale pharmacy licenses in 12 states. The analyst notes a 15% reversal in the stock price from its post-earnings high, also attributing the price target drop to changing investor sentiment and a a lowered terminal growth rate of 1%.
11/20/17
11/20/17
NO CHANGE

Amazon disruption of healthcare 'a foregone conclusion,' says Morgan Stanley
Morgan Stanley's U.S. Internet and Healthcare teams collaborated on a report exploring Amazon's (AMZN) entry into healthcare, stating that it will likely take time but that the e-commerce giant's "disruption of healthcare is a foregone conclusion." While retail plays to Amazon's strengths with the highest profits and lowest barriers to entry, retailers like CVS (CVS) and Walgreens (WBA) have the most opportunities to adjust their business models and lower costs to defend against Amazon, the teams tell investors. Medical supply and Life Sciences distribution are "less rich" targets, but look like "low-hanging fruit," the analysts added. Cardinal Health (CAH) has the most exposure via its medical supply distribution segment, said the firm, which downgraded Cardinal to Underweight from Equal Weight, as previously reported. McKesson (MCK) also has some, but less, risk and AmerisourceBergen (ABC), which doesn't distribute medical supplies, remains immune in the near-term, the firm concluded. Others in healthcare distribution facing the most share and/or margin risk from Amazon include Thermo Fisher (TMO), Henry Schein (HSIC) and Patterson (PDCO), the firm added.
ABC AmerisourceBergen
$84.82

0.16 (0.19%)

10/27/17
JEFF
10/27/17
NO CHANGE
JEFF
Amazon licenses likely related to medical equipment, says Jefferies
News of Amazon.com's (AMZN) receipt of wholesale pharmacy licenses drove a sell-off yesterday in pharma supply chain stocks, Jefferies analyst Brian Tanquilut tells investors in a research note. Shares of AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) fell yesterday in late afternoon trading. The analyst says that while the news strengthened investor fears about Amazon's entry into drug retailing, his due diligence indicates the licenses Amazon obtained are likely associated with its sale and distribution of medical equipment rather than prescription drugs. Tanquilut, however, recognizes that Amazon fears will overhang over prescription supply chain stocks in the near-term. He believes the impact to distributors from Amazon's professional medical device sales and distribution business remains difficult to assess.
11/06/17
NEED
11/06/17
NO CHANGE
Target $86
NEED
Buy
AmerisourceBergen price target lowered to $86 from $93 at Needham
Needham analyst Kevin Caliendo lowered his price target on AmerisourceBergen (ABC) to $86 following Q4 results and initial FY18 guidance. Caliendo says he questions expectations of 3%-5% profit growth amid the management's expectations of increased operating spending. The analyst keeps his Buy rating however, noting that the set-up for FY18 is still appealing, once year-end selling is finished and Amazon's (AMZN) plans on pharmaceutical distribution are disclosed.
CAH Cardinal Health
$59.19

0.08 (0.14%)

11/20/17
11/20/17
DOWNGRADE
Target $51

Underweight
Cardinal Health cut to sell on outsized Amazon risk at Morgan Stanley
As previously reported, Morgan Stanley analyst Ricky Goldwasser downgraded Cardinal Health (CAH) to Underweight, the firm's equivalent to a sell rating, from Equal Weight. It has become clear that Amazon (AMZN) is looking to scale its medical supply distribution efforts and Cardinal's potential earnings risk from Amazon's effort is outsized compared to peers and still underappreciated, said Goldwasser, who added that "price competition is likely a matter of time" as Amazon builds its infrastructure. He cut his price target on Cardinal to $51 from $72.
11/20/17
MSCO
11/20/17
DOWNGRADE
MSCO
Underweight
Cardinal Health downgraded to Underweight from Equal Weight at Morgan Stanley

TODAY'S FREE FLY STORIES

NNBR

NN, Inc.

$26.60

-0.25 (-0.93%)

11:12
12/12/17
12/12
11:12
12/12/17
11:12
Conference/Events
NN, Inc. management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VMC

Vulcan Materials

$122.21

-0.715 (-0.58%)

11:07
12/12/17
12/12
11:07
12/12/17
11:07
Conference/Events
Vulcan Materials management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.64

0.62 (4.13%)

11:05
12/12/17
12/12
11:05
12/12/17
11:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGU

Agrium

$110.72

2.71 (2.51%)

11:04
12/12/17
12/12
11:04
12/12/17
11:04
Hot Stocks
Agrium to acquire Louis Dreyfus Company's Macrofertil fertilizer business »

Agrium announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$47.72

-25.66 (-34.97%)

11:04
12/12/17
12/12
11:04
12/12/17
11:04
Upgrade
Spark Therapeutics rating change  »

Follow-up: Spark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

GRPN

Groupon

$5.86

0.05 (0.86%)

10:57
12/12/17
12/12
10:57
12/12/17
10:57
Recommendations
Groupon analyst commentary  »

Groupon selloff today a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$51.62

0.19 (0.37%)

10:55
12/12/17
12/12
10:55
12/12/17
10:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

10:55
12/12/17
12/12
10:55
12/12/17
10:55
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

ONCE

Spark Therapeutics

$47.72

-25.66 (-34.97%)

10:54
12/12/17
12/12
10:54
12/12/17
10:54
Upgrade
Spark Therapeutics rating change  »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

GSK

GlaxoSmithKline

$35.53

0.22 (0.62%)

10:53
12/12/17
12/12
10:53
12/12/17
10:53
Hot Stocks
FDA approves expanded use of GlaxoSmithKline's Nucala »

The FDA expanded the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TRIP

TripAdvisor

$35.32

0.82 (2.38%)

10:48
12/12/17
12/12
10:48
12/12/17
10:48
Hot Stocks
TripAdvisor, ReviewPush form licensing partnership for restaurant reviews »

ReviewPush announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$55.00

9.925 (22.02%)

, MS

Morgan Stanley

$53.09

0.32 (0.61%)

10:46
12/12/17
12/12
10:46
12/12/17
10:46
Hot Stocks
Overstock rises after Morgan Stanley discloses stake ahead of crypto launch »

Shares of Overstock…

OSTK

Overstock.com

$55.00

9.925 (22.02%)

MS

Morgan Stanley

$53.09

0.32 (0.61%)

BTC

Bitcoin

BITCOIN

Bitcoin

QVCA

QVC Group

$24.52

-0.27 (-1.09%)

TJX

TJX

$73.55

0.25 (0.34%)

COST

Costco

$188.86

0.79 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

ATVI

Activision Blizzard

$63.17

0.74 (1.19%)

, EA

Electronic Arts

$107.92

2.65 (2.52%)

10:44
12/12/17
12/12
10:44
12/12/17
10:44
Hot Stocks
Goldman ups Activision Blizzard, cuts EA in video game ratings shuffle »

Ahead of 2018, Goldman…

ATVI

Activision Blizzard

$63.17

0.74 (1.19%)

EA

Electronic Arts

$107.92

2.65 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

TMUS

T-Mobile

$63.07

0.53 (0.85%)

10:43
12/12/17
12/12
10:43
12/12/17
10:43
Conference/Events
T-Mobile to host business news update conference call »

T-Mobile's President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MMM

3M

$236.76

-2.54 (-1.06%)

10:43
12/12/17
12/12
10:43
12/12/17
10:43
Recommendations
3M analyst commentary  »

3M guidance solid versus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SQ

Square

$39.23

0.9318 (2.43%)

10:40
12/12/17
12/12
10:40
12/12/17
10:40
Options
Sizable put buyer in Square as shares rally »

Sizable put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

WWE

WWE

$30.94

0.24 (0.78%)

10:37
12/12/17
12/12
10:37
12/12/17
10:37
Conference/Events
WWE management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VKTX

Viking Therapeutics

$3.97

-0.11 (-2.70%)

10:35
12/12/17
12/12
10:35
12/12/17
10:35
Conference/Events
Viking Therapeutics management to meet with Maxim »

Meetingsto be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

  • 28

    Dec

TSLA

Tesla

$328.91

13.78 (4.37%)

, PEP

PepsiCo

$117.97

0.58 (0.49%)

10:34
12/12/17
12/12
10:34
12/12/17
10:34
Hot Stocks
Tesla jumps as PepsiCo makes biggest public pre-order of Semi trucks »

Shares of Tesla (TSLA)…

TSLA

Tesla

$328.91

13.78 (4.37%)

PEP

PepsiCo

$117.97

0.58 (0.49%)

WMT

Walmart

$97.02

0.09 (0.09%)

DPSGY

Deutsche Post

$47.34

-0.26 (-0.55%)

JBHT

J.B. Hunt

$111.30

-1.21 (-1.08%)

BUD

AB InBev

$111.30

-0.12 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Jan

  • 20

    Feb

NICE

Nice

$87.68

-0.15 (-0.17%)

10:32
12/12/17
12/12
10:32
12/12/17
10:32
Conference/Events
Nice management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 26

    Feb

EA

Electronic Arts

$107.92

2.65 (2.52%)

10:30
12/12/17
12/12
10:30
12/12/17
10:30
Options
Electronic Arts attracts a bullish option play »

Electronic Arts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

10:30
12/12/17
12/12
10:30
12/12/17
10:30
General news
Euro$ interest rate futures are lower »

Euro$ interest rate…

IPGP

IPG Photonics

$206.65

1.39 (0.68%)

10:29
12/12/17
12/12
10:29
12/12/17
10:29
Conference/Events
IPG Photonics management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

EVI

EnviroStar

$31.45

0.85 (2.78%)

10:25
12/12/17
12/12
10:25
12/12/17
10:25
Hot Stocks
EnviroStar declares 12c per share special cash dividend »

EnviroStar announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KMT

Kennametal

$45.81

-0.15 (-0.33%)

10:25
12/12/17
12/12
10:25
12/12/17
10:25
Conference/Events
Kennametal to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.